Abstract Details

Title Real-world Effectiveness of Intravenous Eptinezumab in Patients with Chronic Migraine and Previous Subcutaneous Preventive Migraine Treatment

Topic Headache

Presentation(s) P8 - Poster Session 8 (5:30 PM-6:30 PM)

Poster/Presentation
Number 12-004

Objective To evaluate whether prior use of subcutaneous anti–calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies (mAbs) impacts the real-world effectiveness of eptinezumab in patients with chronic migraine (CM).

Background Since 2018, several CGRP-targeted therapies have entered the migraine market, including eptinezumab. Minimal evidence exists evaluating the real-world effectiveness of switching from a subcutaneous to an intravenous anti-CGRP mAb.

Design/Methods

An observational, multi-site (n=4), US-based study, REVIEW evaluated real-world experiences of patients with CM treated with eptinezumab using a retrospective chart review, patient survey, and semi-structured physician interview. Adults (≥18 years) with a diagnosis of CM who had completed ≥2 consecutive eptinezumab infusion cycles were eligible. This patient survey analysis focused on the effectiveness of eptinezumab in patients stratified by prior exposure to anti-CGRP mAbs (type and number).

Results Enrolled patients were primarily female (83%, 78/94), had a mean age of 49 years and a mean migraine diagnosis duration of 15.4 years. All patients (94/94) self-reported prior preventive therapy with 89% (84/94) reporting prior subcutaneous anti-CGRP mAb use (i.e., fremanezumab, galcanezumab, or erenumab). Of those who received >1 subcutaneous anti-CGRP prior to eptinezumab, 32% reported one switch (i.e., one anti-CGRP prior to eptinezumab), 38% reported two switches, and 30% reported three switches. Before eptinezumab, patients reported a mean of 8 “good” days/month, which increased to 18 “good” days/month following treatment. Regardless of prior exposure to a CGRP ligand or receptor blocker, the number of “good” days/month more than doubled following eptinezumab. Patients experienced a similar mean change in the number of “good” days/month regardless of the number and type of previous subcutaneous anti-CGRP mAbs used.

Conclusions This real-world, patient survey showed that patients with prior exposure to subcutaneous anti-CGRP mAbs had high overall satisfaction with the effectiveness of eptinezumab treatment regardless of the number and type of previous therapies used.

Authors/Disclosures
Lee Boyle, PhD PRESENTER	No disclosure on file
Charles E. Argoff, MD (Albany Medical Center)	Dr. Argoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nevro. Dr. Argoff has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for XGene. Dr. Argoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vertex. Dr. Argoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Scilex. Dr. Argoff has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Colllegium. Dr. Argoff has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vertex. Dr. Argoff has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan/Abbvie. Dr. Argoff has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Lundbeck. Dr. Argoff has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Scilex. Dr. Argoff has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Scilex. The institution of Dr. Argoff has received research support from Lilly. The institution of Dr. Argoff has received research support from Lundbeck. The institution of Dr. Argoff has received research support from Abbvie. The institution of Dr. Argoff has received research support from Vertex. Dr. Argoff has received publishing royalties from a publication relating to health care.
Steven P. Herzog, MD (Texas Neurology)	Dr. Herzog has nothing to disclose.
Ryan M. Smith, DO, FAAN (St Lukes Neurology)	Dr. Smith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Smith has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie.
Seema Soni-Brahmbhatt	Seema Soni-Brahmbhatt has nothing to disclose.
Susanne Awad (H. Lundbeck A/S)	Susanne Awad has received personal compensation for serving as an employee of Lundbeck.
Divya Asher	Divya Asher has received personal compensation for serving as an employee of Lundbeck. Divya Asher has received personal compensation for serving as an employee of AbbVie.
Fawad A. Khan, MD (Ochsner Health System)	The institution of Dr. Khan has received research support from Amgen .

��ɫ��

��ɫ��